

Resource Summary Report

Generated by [PRECISE-TBI](#) on Sep 7, 2026

SRAMP

RRID:SCR_024500

Type: Tool

Proper Citation

SRAMP (RRID:SCR_024500)

Resource Information

URL: <http://www.cuilab.cn/sramp/>

Proper Citation: SRAMP (RRID:SCR_024500)

Description: Software tool as computational predictor of mammalian m(6)A site. Used for prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features.

Synonyms: Sequence-based Rna Adenosine Methylation site Predictor

Resource Type: simulation software, software application, software resource

Defining Citation: [PMID:26896799](#)

Keywords: mammalian m(6)A site predictor, sequence derived features based predictor,

Availability: Free, Available for download, Freely available

Resource Name: SRAMP

Resource ID: SCR_024500

Record Creation Time: 20231002T161336+0000

Record Last Update: 20260905T133031+0000

Ratings and Alerts

No rating or validation information has been found for SRAMP.

No alerts have been found for SRAMP.

Data and Source Information

Usage and Citation Metrics

We found 452 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Jiang Q, et al. (2026) METTL3-mediated m6A modification of FDX1 confers resistance to cuproptosis and promotes hepatocellular carcinoma progression. *Communications biology*, 9(1), 222.

Chen H, et al. (2026) N6-methyladenosine-mediated up-regulation of ARRB2 regulates intrahepatic cholangiocarcinoma malignant progression and pemigatinib resistance through MAPK and Hippo signaling pathways. *Cell death & disease*, 17(1).

Zhan X, et al. (2026) Construction of a novel risk model for esophageal squamous cell carcinoma associated with purinergic signaling pathways and chemoradiotherapy sensitivity genes. *Frontiers in medicine*, 13, 1746281.

Wang Y, et al. (2026) FTO-mediated m6A demethylation of BCL6 promotes gastric cancer progression by suppressing ferroptosis. *RNA biology*, 23(1), 1.

Liang Y, et al. (2026) The m6A reader protein YTHDF2 facilitates HTLV-1 infectious and mitotic propagation by stabilizing Tax RNA. *Journal of virology*, 100(6), e0052926.

Luan R, et al. (2026) Pan-cancer multi-omics reveals DCAF7 as an immune-modulating prognostic driver and Wnt/ β -catenin activator in hepatocellular carcinoma. *Clinical and translational medicine*, 16(1), e70572.

Chen Q, et al. (2026) YTHDC1-Mediated m6A Modification of MAGI3 mRNA Regulates Proliferation and Differentiation of Myoblasts. *Journal of agricultural and food chemistry*, 74(1), 1804.

Zhang Z, et al. (2026) N6-methyladenosine modification of NEU1 mediated by METTL3 exacerbates angiotensin II-induced atrial fibrillation. *Cell adhesion & migration*, 20(1), 2650272.

Ding X, et al. (2026) Xinfeng capsule attenuates ankylosing spondylitis by downregulating YTHDC1-mediated m6A modification of LINC01579 and suppressing IL-17/NF- κ B signaling. *Frontiers in immunology*, 17, 1762062.

Xiong X, et al. (2026) Methyltransferase-Like 14 Promotes the Angiogenesis of Hepatocellular Carcinoma via Targeting Vascular Endothelial Growth Factor A. *Cancer reports (Hoboken, N.J.)*, 9(6), e70592.

Tang YZ, et al. (2026) Circ_0006174 Drives Triple Negative Breast Cancer Progression and Immune Escape Through Regulating miR-3139/PD-L1 Axis. *The Kaohsiung journal of medical sciences*, 42(6), e70156.

Wang Y, et al. (2026) METTL3 inhibits LINC00312 to suppress osteoporosis progression in a YTHDF2-dependent manner. *International journal of molecular medicine*, 57(1).

Jiang R, et al. (2026) Methyltransferase like 3 promotes thyroid folliculogenesis via coordinating cell differentiation and polarization. *Journal of translational internal medicine*, 14(1), 96.

Liu Y, et al. (2026) ALKBH5 promotes ovarian cancer progression by activating Notch2 signaling. *Biological procedures online*, 28(1).

Du T, et al. (2026) ALKBH5 facilitates Srgn stability via m6A demethylation to disrupt blood-testis barrier integrity in the high-fat diet mice. *Cellular and molecular life sciences : CMLS*, 83(1).

Zhang D, et al. (2026) Dynamic m⁶A methylation during bovine preadipocyte differentiation and functional implication of the m⁶A writer METTL14. *BMC genomics*, 27(1).

Qiu K, et al. (2026) RBM15/IGF2BP2-PTPRH m6A regulatory axis in non-small cell lung cancer. *Cellular oncology (Dordrecht, Netherlands)*, 49(3).

Cheng J, et al. (2026) ADAMDEC1-driven CCL2-CCR2-PD-1 axis in esophageal squamous cell carcinoma: a dual threat of O-GlcNAcylation and m6A methylation in neoadjuvant therapy resistance and immune evasion. *Cellular oncology (Dordrecht, Netherlands)*, 49(2).

Ren H, et al. (2026) The PRKN/METTL3/CLDN2 axis promotes colorectal cancer development through epigenetic mechanisms. *Cell biology and toxicology*, 42(1).

Li L, et al. (2026) Diabetic Kidney Disease Progression Alleviated in Mice by ALKBH5-Mediated UC-MSCs-Derived Exosomes That Inhibit TRAF6 m6A Modification and Promote M2 Macrophage Polarisation. *Endocrinology, diabetes & metabolism*, 9(1), e70131.